Cathepsin Z Specific Monoclonal Antibody and Use thereof

A monoclonal antibody targeting cathepsin Z addresses the limitations of glioblastoma treatment by inhibiting tumor formation and providing a diagnostic tool for glioblastoma, enhancing treatment efficacy and diagnostic accuracy.

KR103045491B1Active Publication Date: 2026-11-11NBIOS INC +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020230059737
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-12-22
Filing Date
2023-05-09
Publication Date
2026-11-11
Estimated Expiration
2043-05-09

AI Technical Summary

Technical Problem

Current treatments for glioblastoma, particularly glioblastoma multiforme, are ineffective due to genetic mutations and the presence of the blood-brain barrier, leading to low survival rates and limited therapeutic options, with cathepsin Z being a key factor in tumor formation and cancer cell invasion.

Method used

Development of a monoclonal antibody specifically binding to cathepsin Z, inhibiting its biological activity, and providing a diagnostic tool for glioblastoma through antigen-antibody complex formation.

Benefits of technology

The monoclonal antibody effectively inhibits tumor formation in cathepsin Z-overexpressing cancers, particularly glioblastoma, and enables accurate diagnosis by binding to cathepsin Z, offering a potential treatment and diagnostic solution for glioblastoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023051241923-PAT00034_ABST
    Figure 112023051241923-PAT00034_ABST
Patent Text Reader

Abstract

The present invention relates to a monoclonal antibody that specifically binds to cathepsin Z and its uses. The monoclonal antibody of the present invention that specifically binds to cathepsin Z, or its antigen-binding fragment, can inhibit the in vivo tumor formation of CtsZ-overexpressing cancers, specifically brain cancers, and more specifically mesenchymal brain cancer stem cells by specifically binding to CtsZ. Accordingly, it can be usefully utilized for the treatment of patients with CtsZ-overexpressing cancers, preferably patients with mesenchymal brain cancers, and more preferably patients with glioblastoma. Furthermore, the monoclonal antibody of the present invention, or its antigen-binding fragment, can enable the diagnosis of CtsZ-overexpressing cancers, specifically brain cancers, and more specifically glioblastoma by specifically binding to cathepsin Z.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a monoclonal antibody that specifically binds to cathepsin Z and its uses. Background Technology

[0002] Cancer is one of the most common causes of death worldwide. Approximately 10 million new cases occur annually, accounting for about 12% of all deaths and making it the third leading cause of death. Among the various types of cancer, brain cancer occurs regardless of age, but it is characterized by a higher incidence in children compared to other cancers. Brain cancer is classified into primary brain tumors, which originate in brain tissue and the meninges surrounding the brain, and secondary brain tumors, which metastasize from cancer in the skull or other parts of the body. Symptoms include focal symptoms such as motor paralysis, sensory paralysis, speech disorders, visual impairments, and balance disorders, as well as symptoms of increased intracranial pressure. Unlike cancers that develop in other tissues, where one or two types of cancer occur tissue-specifically, the brain cancer mentioned above includes various types of cancer such as glioblastoma multiforme, malignant glioma, lymphoma, germ cell tumor, and metastatic tumor. Among these, glioma, and particularly glioblastoma, is the most malignant and aggressive, resulting in a very poor prognosis and a fatal disease with an average survival period of no more than about one year after diagnosis. It is known that in patients with glioblastoma, it is almost impossible to surgically remove the cancerous tissue completely because the boundary between brain cells and tumor cells is not clear.

[0003] Accordingly, although various studies are being conducted to develop a method for treating the aforementioned glioblastoma, the average survival rate of glioblastoma patients remains significantly low even with the current use of the combination therapy method because glioblastoma contains various genetic mutations, thus requiring the development of a new treatment.

[0004] Meanwhile, in the case of the aforementioned brain tumors, the presence of the blood-brain barrier makes it difficult to deliver therapeutic drugs to the target brain region; furthermore, the reality is that the development of treatments has not been active due to a relative lack of understanding of neurobiology. Moreover, compared to other brain tumors, glioblastoma exhibits aggressive variants, which can lead to fatal consequences within a few weeks if not treated promptly.

[0005] Meanwhile, cathepsin Z (hereinafter referred to as 'CtsZ') is known to induce tumor formation and cancer cell invasion in various tumors, particularly mesenchymal glioblastoma multiforme. For example, the above cathepsin Z may be human cathepsin Z, and protein information of human cathepsin Z is registered in the NCBI (National Center for Biotechnology Information) under Accession No. AAH42168.1, etc., and information of the gene encoding it is registered in the NCBI under Accession No. AAV38718.1, etc. It is known that the above CtsZ is associated with tumor formation and cancer cell invasion, and is overexpressed in brain cancer, particularly in mesenchymal glioblastoma stem cells (GSC; Glioblastoma stem cell).

[0006] In this regard, the inventors of the present application have made diligent efforts to develop a monoclonal antibody capable of specifically binding to the CtsZ and effectively inhibiting the biological activity of CtsZ. As a result, they have newly synthesized a monoclonal antibody that specifically binds to human CtsZ from an antibody library, and said antibody inhibits the biological activity of CtsZ, specifically CtsZ-overexpressing cancer, specifically brain cancer, and more specifically mesenchymal brain cancer stem cells. in vivoIt was confirmed that tumor formation is effectively inhibited, and the present invention was completed. Prior art literature

[0007] (Patent Document 0001) KR 10-2021-0136707 A The problem to be solved

[0008] One object of the present invention is to provide a monoclonal antibody or its antigen-binding fragment that specifically binds to cathepsin Z.

[0009] Another object of the present invention is to provide a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, an expression vector comprising the polynucleotide, and a transformant into which the expression vector has been introduced.

[0010] Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of glioblastoma comprising the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0011] Another object of the present invention is to provide a composition for diagnosing glioblastoma comprising the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0012] Another object of the present invention is to provide a diagnostic kit for glioblastoma comprising the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0013] Another objective of the present invention is to provide a method for providing information necessary for the diagnosis of glioblastoma, comprising: (a) contacting the monoclonal antibody, or its antigen-binding fragment, with a biological sample isolated from an individual suspected of having glioblastoma; (b) measuring the expression level of cathepsin Z protein bound to the monoclonal antibody, or its antigen-binding fragment, in the biological sample through the formation of an antigen-antibody complex; and (c) determining that the individual has glioblastoma if the expression level of cathepsin Z protein measured in step (b) is higher than that of a control group. means of solving the problem

[0014] To achieve the above objective, the present invention relates to a monoclonal antibody or its antigen-binding fragment that specifically binds to cathepsin Z, comprising any one heavy chain variable region and a light chain variable region selected from the group consisting of 1) to 9) below:

[0015] 1) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 1, a CDR2 region described as SEQ ID NO. 2, and a CDR3 region described as SEQ ID NO. 3, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 4, a CDR2 region described as SEQ ID NO. 5, and a CDR3 region described as SEQ ID NO. 6;

[0016] 2) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 7, a CDR2 region described as SEQ ID NO. 8, and a CDR3 region described as SEQ ID NO. 9, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 10, a CDR2 region described as SEQ ID NO. 11, and a CDR3 region described as SEQ ID NO. 12;

[0017] 3) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 13, a CDR2 region described as SEQ ID NO. 14, and a CDR3 region described as SEQ ID NO. 15, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 16, a CDR2 region described as SEQ ID NO. 17, and a CDR3 region described as SEQ ID NO. 18;

[0018] 4) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 19, a CDR2 region described as SEQ ID NO. 20, and a CDR3 region described as SEQ ID NO. 21, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 22, a CDR2 region described as SEQ ID NO. 23, and a CDR3 region described as SEQ ID NO. 24;

[0019] 5) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 25, a CDR2 region described as SEQ ID NO. 26, and a CDR3 region described as SEQ ID NO. 27, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 28, a CDR2 region described as SEQ ID NO. 29, and a CDR3 region described as SEQ ID NO. 30;

[0020] 6) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 31, a CDR2 region described as SEQ ID NO. 32, and a CDR3 region described as SEQ ID NO. 33, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 34, a CDR2 region described as SEQ ID NO. 35, and a CDR3 region described as SEQ ID NO. 36;

[0021] 7) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 37, a CDR2 region described as SEQ ID NO. 38, and a CDR3 region described as SEQ ID NO. 39, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 40, a CDR2 region described as SEQ ID NO. 41, and a CDR3 region described as SEQ ID NO. 42;

[0022] 8) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 43, a CDR2 region described as SEQ ID NO. 44, and a CDR3 region described as SEQ ID NO. 45, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 46, a CDR2 region described as SEQ ID NO. 47, and a CDR3 region described as SEQ ID NO. 48; and

[0023] 9) A heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 49, a CDR2 region described as SEQ ID NO. 50, and a CDR3 region described as SEQ ID NO. 51, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 52, a CDR2 region described as SEQ ID NO. 53, and a CDR3 region described as SEQ ID NO. 54.

[0024] In one embodiment of the present invention, the antigen-binding fragment may be selected from the group consisting of Fab, Fab', F(ab')2, scFv, Fv, dsFv, diabody, Fd, and Fd'.

[0025] In addition, the present invention relates to a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment.

[0026] In one embodiment of the present invention, the polynucleotide may be composed of any one sequence selected from SEQ ID NOs 73 to 81.

[0027] In addition, the present invention relates to an expression vector comprising the above-mentioned polynucleotide.

[0028] In addition, the present invention relates to a transformant transformed with the expression vector.

[0029] In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of cathepsin Z overexpressing cancer comprising, as an active ingredient, the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0030] In one embodiment of the present invention, the cancer may be brain cancer.

[0031] In one embodiment of the present invention, the brain cancer may be a malignant brain cancer or a brain tumor.

[0032] In one embodiment of the present invention, the malignant brain cancer may be glioblastoma or glioblastoma multiforme.

[0033] In one embodiment of the present invention, the brain tumor may be an anaplastic astrocytoma.

[0034] In addition, the present invention relates to a composition for diagnosing cathepsin Z overexpressing cancer comprising the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0035] In addition, the present invention relates to a diagnostic kit for cathepsin Z overexpressing cancer comprising the above composition and instructions.

[0036] In addition, the present invention relates to a method for providing information necessary for the diagnosis of a cathepsin Z overexpressing cancer, comprising: (a) contacting the monoclonal antibody, or its antigen-binding fragment, with a biological sample isolated from an individual suspected of having glioblastoma; (b) measuring the expression level of a cathepsin Z protein bound to the monoclonal antibody, or its antigen-binding fragment, in the biological sample through the formation of an antigen-antibody complex; and (c) determining that the cancer is cathepsin Z overexpressing cancer if the expression level of the cathepsin Z protein measured in step (b) is higher than that of a control group. Effects of the invention

[0037] The monoclonal antibody of the present invention that specifically binds to cathepsin Z, or its antigen-binding fragment, specifically binds to CtsZ, thereby enabling CtsZ-overexpressing cancers, specifically brain cancers, and more specifically mesenchymal brain cancer stem cells. in vivo Tumor formation can be inhibited. Accordingly, it can be usefully utilized for the treatment of patients with CtsZ overexpressing cancer, preferably patients with mesenchymal brain cancer, and more preferably patients with glioblastoma. In addition, the monoclonal antibody of the present invention, or its antigen-binding fragment, can enable the diagnosis of CtsZ overexpressing cancer, specifically brain cancer, and more specifically glioblastoma, by specifically binding to cathepsin Z. Brief explanation of the drawing

[0038] Figure 1 is a schematic diagram briefly showing the structure of CtsZ according to the present invention. Figure 2 is the RT-PCR result of human CtsZ cDNA according to one embodiment of the present invention. Figure 3 is the result of purifying a medium released from CtsZ using a Ni-NTA affinity column according to one embodiment of the present invention. Figure 4 is the result of confirming the expression of CtsZ by Western blot using an anti-6X his tag antibody according to one embodiment of the present invention. Figure 5 is a graph showing the binding affinity of integrin αVβ3 binding to purified CtsZ according to one embodiment of the present invention. FIG. 6 is a schematic diagram briefly illustrating the bonding principle of CNBr activating resin and CtsZ according to one embodiment of the present invention, and the result resulting from said bonding. Figure 7 is an amino acid sequence structure of an OPAL phage display library according to one embodiment of the present invention. FIG. 8 is a schematic diagram briefly illustrating a biopanning procedure according to one embodiment of the present invention. FIGS. 9 and 10 show the input, output, and output / input phage titers according to each round in the primary biopanning process according to one embodiment of the present invention. FIG. 11a shows the results of a dot blot analysis of the 3-round output of the primary biopanning according to one embodiment of the present invention, FIG. 11b shows the results of a plate binding test performed to confirm whether the purified CtsZ antigen binds to the plate according to one embodiment of the present invention, and FIG. 11c shows the CtsZ binding strength of the 3-round output of the primary biopanning according to one embodiment of the present invention. FIG. 12a shows the dot blot analysis results for the 4 round output of primary biopanning according to one embodiment of the present invention, and FIG. 12b shows the CtsZ binding strength for the 4 round output of primary biopanning according to one embodiment of the invention. FIGS. 13 and 14 show the input, output, and output / input phage titers according to each round in a secondary biopanning process according to an embodiment of the present invention. FIG. 15a shows the results of a dot blot analysis of the 4-round output of secondary biopanning according to one embodiment of the present invention, and FIG. 15b shows the CtsZ binding strength of the 4-round output of secondary biopanning according to one embodiment of the present invention. FIGS. 16a and 16b are scFv ELISA results for each clone according to 3 rounds of primary biopanning and 4 rounds of secondary biopanning according to one embodiment of the present invention. FIG. 17a shows the results of a dot blot analysis of the 5 round output of secondary biopanning according to one embodiment of the present invention, and FIG. 17b shows the CtsZ binding strength of the 5 round output of secondary biopanning according to one embodiment of the present invention. Figure 18 shows the scFv ELISA results for each clone according to 5 rounds of secondary biopanning according to one embodiment of the present invention. Figure 19 is the result of analyzing the sequences of 96 types of scFv specific to CtsZ selected according to one embodiment of the present invention. FIG. 20 shows the specific sequences of 12 AE types among a total of 39 clones obtained by excluding enriched sequences from 96 types of scFv specific to CtsZ selected according to one embodiment of the present invention. FIG. 21 shows the specific sequences of 10 BE clones among a total of 39 clones obtained by excluding enriched sequences from 96 scFvs specific to CtsZ selected according to one embodiment of the present invention. FIG. 22 shows the specific sequences of 10 CF types among a total of 39 clones obtained by excluding enriched sequences from 96 types of scFv specific to CtsZ selected according to one embodiment of the present invention. FIG. 23 shows the specific sequences of 7 types of DF among a total of 39 types of clones obtained by excluding enriched sequences from among 96 types of scFv specific to CtsZ selected according to one embodiment of the present invention. FIG. 24 is an ELISA analysis result showing the binding strength of CtsZ, integrin αVβ3, and fibronectin, respectively, of CtsZ-specific scFv selected according to one embodiment of the present invention. FIG. 25 shows the specific sequences of a total of 9 types of scFv specific to CtsZ finally selected according to one embodiment of the present invention. FIG. 26 shows the purity and KD values ​​by SDS-PAGE analysis of a total of 9 types of scFv specific to CtsZ finally selected according to one embodiment of the present invention. Figure 27 shows a histogram of apoptosis through FACS (cell cycle) analysis after treating 83NS cells with the anti-CtsZ antibody of the present invention according to one embodiment of the present invention. Figure 28 shows a quantitative graph of apoptosis through FACS (cell cycle) analysis after treating 83NS cells with the anti-CtsZ antibody of the present invention according to one embodiment of the present invention. Specific details for implementing the invention

[0039] The present invention will be described in detail below.

[0040] The present invention provides a monoclonal antibody that specifically binds to cathepsin Z, or an antigen-binding fragment thereof. The CtsZ is characterized by being specific to cathepsin Z-overexpressing cancers, preferably brain cancers, more preferably malignant brain cancers or brain tumors, and even more preferably glioblastoma (e.g., specifically expressed in glioblastoma).

[0041] In the present invention, the term “cathepsin” refers to an enzyme present in lysosomes that induces the degradation of damaged proteins through the endosome-lysosome pathway. These cathepsins are classified into cysteine, aspartate, and serine cathepsins depending on the catalytic residue site at which they are activated. Eleven isozymes (B, C, F, H, K, L, O, S, V, Z, and W) of the cathepsin are known to be expressed more frequently in various tumor types, exhibit an inverse correlation with the survival rates of these patients, and play an important role in tumor formation and evolution. Among these, cathepsin Z (hereinafter referred to as 'CtsZ') differs from other members of the cathepsin family in that it possesses an RGD peptide sequence in its pro-domain. After being secreted extracellularly, it binds to integrins in the cancer cell itself and surrounding cells via autocrine and paracrine mechanisms, thereby transmitting tumor-promoting signals into the cancer cell.

[0042] In the present invention, the term “cathepsin Z” plays an important role in the disease microenvironment because, unlike other cysteine ​​cathepsins, it maintains stable activity even in a neutral pH environment and has the characteristic of having limited expression in specific tissues. In immune cells, CtsZ regulates the immune response by activating MHC class II, which is important for antigen presentation, through the degradation of the invariant chain, while in cancer cells, CtsZ plays a role in increasing cancer cell growth by regulating metastasis and angiogenesis. In particular, inhibition and defects in the expression of CtsZ in cancer cells not only inhibit angiogenesis but also reduce cancer cell growth and metastasis and induce apoptosis. The aforementioned CtsZ is known to have high expression in liver, colorectal, and prostate cancers, and its expression increases when inflammation occurs in the stomach due to Helicobacter pylori infection. It has also been reported to play an important role in tumor malignancy in pancreatic cancer models, but its role in malignant brain cancer is not well known (Nagler DK et al., Prostate. 2004 Jul 1;60(2):109-19. / Wang J et al., PLoS One. 2011;6(9):e24967. / Vizin T et al., BMC Cancer. 2014 Apr 13;14:259. / Krueger S et al., J Pathol. 2005 Sep;207(1):32-42. / Bernhardt A et al., J Biol Chem. 2010 Oct 29;285(44):33691-700. / Akkri L et al. Genes Dev. 2014 Oct 1;28(19):2134-50). As mentioned above, given that CtsZ plays an important role in tumor formation and development in other epithelial carcinomas, CtsZ, which is significantly increased in expression in MES brain cancer, has high value as an important therapeutic target in MES brain cancer, which is highly resistant to treatment.

[0043] The inventors identified an antibody that specifically recognizes CtsZ and determined the amino acids of its heavy chain variable region, the amino acids of its light chain variable region, and the coding nucleotide sequence.

[0044] In addition, as a preferred embodiment, the present invention can enable the accurate diagnosis of cathepsin Z overexpressing cancers, preferably one or more cancers selected from brain cancer, liver cancer, colorectal cancer and prostate cancer, more preferably malignant brain cancer or brain tumor, more preferably glioblastoma, glioblastoma multiforme or anaplastic astrocytoma, more preferably glioblastoma cells and / or tissues by providing a monoclonal antibody that specifically binds to CtsZ or an antigen-binding fragment thereof, thereby specifically detecting CtsZ.

[0045] In the present invention, the term "antibody" refers to a protein molecule that acts as a receptor for specifically recognizing an antigen, comprising an immunoglobulin molecule that is immunologically reactive with a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, complete antibody forms, as well as antigen-binding fragments (antibody fragments) of antibody molecules. Additionally, the term includes chimeric antibodies, humanized antibodies, and bivalent or bispecific molecules (e.g., bispecific antibodies), diabadies, triabadies, and tetraabadies.

[0046] The "complete antibody" has a structure having two full-length light chains and two full-length heavy chains, each light chain being connected to the heavy chain by a disulfide bond. The complete antibody includes IgA, IgD, IgE, IgM, and IgG, and IgG includes subtypes IgG1, IgG2, IgG3, and IgG4.

[0047] In this specification, the term "antigen-binding fragment of an antibody" refers to a fragment possessing antigen-antibody binding function within a complete antibody molecule, and includes Fab, Fab', F(ab')2, scFv, Fv, dsFv, diabody, Fd, and Fd'. Fab has a structure having variable regions of the light and heavy chains, a constant region of the light chain, and a first constant region of the heavy chain (CH1 domain), and possesses one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. The F(ab')2 antibody is generated when the cysteine ​​residues in the hinge region of Fab' form disulfide bonds. Fv (variable fragment) refers to a minimal antibody fragment possessing only the heavy chain variable region and the light chain variable region. Double-stranded Fv (dsFv) has a heavy chain variable region and a light chain variable region connected by a disulfide bond, while single-stranded Fv (scFv) generally has a heavy chain variable region and a light chain variable region connected by a covalent bond via a peptide linker or directly connected at the C-terminus, so that they can form a dimer-like structure similar to double-stranded Fv. A diabody is a complex of two or more polypeptide chains or proteins, each containing at least one VL and VH domain or fragment thereof, and both domains contained within a single polypeptide chain. In some embodiments, the diabody includes a molecule containing an Fc or hinge-Fc domain. The polypeptide chains of such a complex may be identical or different; that is, the diabody may be a monomer or a heteromer.

[0048] These antigen-binding fragments can be obtained using proteolytic enzymes (for example, Fab can be obtained by restricting a complete antibody with papain and F(ab')2 fragment can be obtained by cleaving it with pepsin), and preferably, they can be produced through recombinant technology.

[0049] In this specification, the term “heavy chain” refers to both the full-length heavy chain and fragments thereof, comprising a variable region domain VH and three constant region domains CH1, CH2, and CH3, which include an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen. Additionally, the term “light chain” refers to both the full-length light chain and fragments thereof, comprising a variable region domain VL and a constant region domain CL, which include an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen.

[0050] In the present invention, the term “monoclonal antibody” refers to an antibody molecule of a single molecular composition obtained from substantially the same group of antibodies, and such monoclonal antibodies exhibit single-binding specificity and affinity for a specific epitope. Typically, immunoglobulins have a heavy chain and a light chain, and each heavy chain and light chain includes a constant region and a variable region (said regions are also known as domains). The variable regions of the light chain and heavy chain include three variable regions called complementarity-determining regions (hereinafter referred to as “CDRs”) and four framework regions (FRs). The CDRs serve primarily to bind to the epitopes of the antigen. The CDRs of each chain are typically referred to sequentially as CDR1, CDR2, CDR3 starting from the N-terminus, and are also identified by the chain in which a specific CDR is located.

[0051] In this specification, the term “CDR (complementarity determining region)” refers to the amino acid sequence of a hypervariable region of an immunoglobulin heavy chain and light chain (Kabat et al. Sequences of Proteins of Immunological Interest, 4th Ed., US Department of Health and Human Services, National Institutes of Health (1987)). The heavy chains (CDRH1, CDRH2, and CDRH3) and light chains (CDRL1, CDRL2, and CDRL3) each contain three CDRs, and these CDRs provide major contact residues for the antibody to bind to an antigen or epitope.

[0052] Meanwhile, the above monoclonal antibody may be a chimeric antibody or humanized antibody with reduced immunogenicity for application to the human body as described above, or it may be a human antibody.

[0053] In the present invention, the term "chimeric antibody" refers to an antibody in which the variable region of an antibody that is heterogeneous to humans, such as in mice and chickens, and the constant region of a human antibody are recombined using DNA recombination technology. Since the immune response of the chimeric antibody is significantly improved compared to that of the antibody that is heterogeneous to humans, such as in mice and chickens, it can be used clinically.

[0054] In the present invention, the term "humanized antibody" refers to an antibody in which all or part of the CDR sequence of a monoclonal antibody that is heterogeneous to humans, such as mice or chickens, is transplanted into a human antibody. For example, a humanized variable region can be prepared by recombining CDRs from a chicken or mouse monoclonal antibody with FR derived from a human antibody, and then recombining this with a preferred constant region of a human antibody, but is not limited thereto. Furthermore, since the affinity of the humanized antibody decreases when only the CDRs derived from chickens or mice are transplanted, the affinity can be enhanced by substituting FR amino acid residues, which are thought to affect the three-dimensional structure of the CDR, with amino acids from the chicken or mouse antibody, but is not limited thereto.

[0055] In the present invention, the term "monoclonal antibody specifically binding to cathepsin Z" refers to an antibody capable of specifically binding to CtsZ, and may be used interchangeably with "anti-CtsZ antibody" in the present invention. The monoclonal antibody specifically binding to the CtsZ protein includes, without limitation, any monoclonal antibody that binds to CtsZ and inhibits the biological activity of CtsZ. Furthermore, as described above, the form of the monoclonal antibody may include both a complete antibody and an antigen-binding fragment, and may be a chimeric antibody or a humanized antibody, but is not limited thereto. In addition, the monoclonal antibody of the present invention specifically binds to CtsZ and inhibits signal transduction by CtsZ, thereby inhibiting biological activity. Therefore, it can be usefully employed in the prevention or treatment of diseases involving CtsZ, specifically cathepsin Z overexpressing cancer, preferably one or more cancers selected from brain cancer, liver cancer, colorectal cancer and prostate cancer, more preferably malignant brain cancer or brain tumor, more preferably glioblastoma, glioblastoma multiforme or anaplastic astrocytoma, and more preferably glioblastoma.In addition, since overexpression of CtsZ is reported to be a specific phenomenon in one or more types of cancer selected from brain cancer, liver cancer, colorectal cancer, and prostate cancer, preferably malignant brain cancer or brain tumor, more preferably glioblastoma, glioblastoma multiforme, or anaplastic astrocytoma, and more preferably glioblastoma, the antibody of the present invention, which can specifically bind to CtsZ, has a diagnostic ability with high sensitivity and specificity in the diagnosis of cathepsin Z overexpressing cancer, preferably one or more types of cancer selected from brain cancer, liver cancer, colorectal cancer, and prostate cancer, more preferably malignant brain cancer or brain tumor, more preferably glioblastoma, glioblastoma multiforme, or anaplastic astrocytoma, and more preferably glioblastoma, and can be usefully used in the diagnosis of said cancer. In one embodiment of the present invention, an antigen-binding fragment that specifically binds to the CtsZ of the present invention was prepared using CtsZ as an antigen protein.

[0056] The monoclonal antibody specifically binding to the above CtsZ, or its antigen-binding fragment, may comprise any one heavy chain variable region and light chain variable region selected from the group consisting of 1) to 9) below, but is not limited thereto:

[0057] 1) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 1, a CDR2 region described as SEQ ID NO. 2, and a CDR3 region described as SEQ ID NO. 3, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 4, a CDR2 region described as SEQ ID NO. 5, and a CDR3 region described as SEQ ID NO. 6;

[0058] 2) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 7, a CDR2 region described as SEQ ID NO. 8, and a CDR3 region described as SEQ ID NO. 9, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 10, a CDR2 region described as SEQ ID NO. 11, and a CDR3 region described as SEQ ID NO. 12;

[0059] 3) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 13, a CDR2 region described as SEQ ID NO. 14, and a CDR3 region described as SEQ ID NO. 15, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 16, a CDR2 region described as SEQ ID NO. 17, and a CDR3 region described as SEQ ID NO. 18;

[0060] 4) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 19, a CDR2 region described as SEQ ID NO. 20, and a CDR3 region described as SEQ ID NO. 21, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 22, a CDR2 region described as SEQ ID NO. 23, and a CDR3 region described as SEQ ID NO. 24;

[0061] 5) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 25, a CDR2 region described as SEQ ID NO. 26, and a CDR3 region described as SEQ ID NO. 27, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 28, a CDR2 region described as SEQ ID NO. 29, and a CDR3 region described as SEQ ID NO. 30;

[0062] 6) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 31, a CDR2 region described as SEQ ID NO. 32, and a CDR3 region described as SEQ ID NO. 33, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 34, a CDR2 region described as SEQ ID NO. 35, and a CDR3 region described as SEQ ID NO. 36;

[0063] 7) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 37, a CDR2 region described as SEQ ID NO. 38, and a CDR3 region described as SEQ ID NO. 39, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 40, a CDR2 region described as SEQ ID NO. 41, and a CDR3 region described as SEQ ID NO. 42;

[0064] 8) a heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 43, a CDR2 region described as SEQ ID NO. 44, and a CDR3 region described as SEQ ID NO. 45, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 46, a CDR2 region described as SEQ ID NO. 47, and a CDR3 region described as SEQ ID NO. 48; and

[0065] 9) A heavy chain variable region comprising a CDR1 region described as SEQ ID NO. 49, a CDR2 region described as SEQ ID NO. 50, and a CDR3 region described as SEQ ID NO. 51, and a light chain variable region comprising a CDR1 region described as SEQ ID NO. 52, a CDR2 region described as SEQ ID NO. 53, and a CDR3 region described as SEQ ID NO. 54.

[0066] In one embodiment of the present invention, the antigen-binding fragment is preferably, but not limited to, Fab, Fab', F(ab')2, scFv, Fv, dsFv, diabody, Fd, Fd', a light chain or heavy chain comprising the CDR site of the present invention, or a variable domain comprising the CDR site of the present invention.

[0067] In another embodiment of the present invention, the monoclonal antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising a polypeptide sequence described as SEQ ID NO. 55 and a light chain variable region comprising a polypeptide sequence described as SEQ ID NO. 56; a heavy chain variable region comprising a polypeptide sequence described as SEQ ID NO. 57 and a light chain variable region comprising a polypeptide sequence described as SEQ ID NO. 58; a heavy chain variable region comprising a polypeptide sequence described as SEQ ID NO. 59 and a light chain variable region comprising a polypeptide sequence described as SEQ ID NO. 60; a heavy chain variable region comprising a polypeptide sequence described as SEQ ID NO. 61 and a light chain variable region comprising a polypeptide sequence described as SEQ ID NO. 62; a heavy chain variable region comprising a polypeptide sequence described as SEQ ID NO. 63 and a light chain variable region comprising a polypeptide sequence described as SEQ ID NO. 64; It is preferable to include a heavy chain variable region and a light chain variable region selected from the group consisting of: a heavy chain variable region including a polypeptide sequence described as SEQ ID NO. 65 and a light chain variable region including a polypeptide sequence described as SEQ ID NO. 66; a heavy chain variable region including a polypeptide sequence described as SEQ ID NO. 67 and a light chain variable region including a polypeptide sequence described as SEQ ID NO. 68; a heavy chain variable region including a polypeptide sequence described as SEQ ID NO. 69 and a light chain variable region including a polypeptide sequence described as SEQ ID NO. 70; and a heavy chain variable region including a polypeptide sequence described as SEQ ID NO. 71 and a light chain variable region including a polypeptide sequence described as SEQ ID NO. 72.

[0068] All mutants of the antibody or its antigen-binding fragment of the present invention that achieve the intended effect of the present invention through one or more mutations, such as substitutions, deletions, inversions, or translocations, in the antibody limited by the sequence are also included within the scope of protection of the present invention.

[0069] The antibody or its antigen-binding fragment of the present invention exhibits high apoptotic activity in cathepsin Z overexpressing cancers, preferably one or more cancers selected from brain cancer, liver cancer, colorectal cancer and prostate cancer, more preferably malignant brain cancer or brain tumor, more preferably glioblastoma, glioblastoma multiforme or anaplastic astrocytoma, more preferably glioblastoma, and can inhibit tumor formation.

[0070] According to one embodiment of the present invention, the monoclonal antibody of the present invention, which specifically binds to CtsZ, exhibited high apoptotic activity in mesenchymal glioblastoma stem cells.

[0071] In addition, the present invention provides a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment.

[0072] The above polynucleotide may be a sequence selected from the group consisting of SEQ ID NOs 73 to 81, but is not limited thereto.

[0073] In another aspect, the present invention provides an expression vector comprising the polynucleotide and a transformant into which the vector is introduced.

[0074] The expression vector comprising the polynucleotide encoding the monoclonal antibody provided in the present invention is not particularly limited thereto, but may be a vector capable of replicating and / or expressing the polynucleotide in eukaryotic or prokaryotic cells including mammalian cells (e.g., human, monkey, rabbit, rat, hamster, mouse cells, etc.), plant cells, yeast cells, insect cells, or bacterial cells (e.g., E. coli, etc.), and preferably may be a vector comprising at least one selection marker that is operably linked to a suitable promoter so that the nucleotide can be expressed in a host cell. Examples include the polynucleotide being introduced into a phage, plasmid, cosmid, mini-chromosome, virus, or retroviral vector, etc.

[0075] An expression vector comprising a polynucleotide encoding the monoclonal antibody may be an expression vector comprising a polynucleotide encoding the heavy chain or light chain of the monoclonal antibody, respectively, or an expression vector comprising both polynucleotides encoding the heavy chain and the light chain.

[0076] The transformant into which the expression vector provided in the present invention is introduced is not particularly limited thereto, but may be a bacterial cell such as Escherichia coli, Streptomyces, or Salmonella typhimurium; a yeast cell; a fungal cell such as Pichia pastoris; an insect cell such as Drozophylla or Spodoptera Sf9 cell; an animal cell such as CHO (Chinese hamster ovary cells), SP2 / 0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), 293T, Bow melanoma cell, HT-1080, BHK (baby hamster kidney cells), HEK (human embryonic kidney cells), PERC.6 (human retinal cell); or a plant cell.

[0077] In the present invention, the term "introduction" refers to a method of delivering a vector containing a polynucleotide encoding the monoclonal antibody to a host cell. Such introduction may be carried out by various methods known in the art, such as calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroshock, microinjection, liposome fusion, lipofectamine, and protoplast fusion. Furthermore, introduction refers to delivering a target into a cell using viral particles by means of infection. In addition, the vector may be introduced into a host cell by means of gene bombardment, etc. In the present invention, introduction may be used interchangeably with transformation.

[0078] It is preferable that the host cell of the present invention be an 'isolated' host cell.

[0080] In another aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of cathepsin Z overexpressing cancer comprising, as an active ingredient, the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0081] Since the “monoclonal antibody, or its antigen-binding fragment” and “cathepsin Z overexpressing cancer” of the present invention have already been described above, the description thereof is omitted to avoid excessive duplication.

[0082] In the present invention, the cancer may be one or more selected from brain cancer, liver cancer, colorectal cancer and prostate cancer.

[0083] In the present invention, the brain cancer may be a malignant brain cancer or a brain tumor.

[0084] In the present invention, the malignant brain cancer may be glioblastoma or glioblastoma multiforme.

[0085] In the present invention, the brain tumor may be an anaplastic astrocytoma.

[0086] In the present invention, the term "prevention" may refer to any act of suppressing or delaying the onset of cathepsin Z overexpressing cancer by administering the above composition. Additionally, in the present invention, the term "treatment" may refer to any act of improving or beneficially altering the symptoms of cathepsin Z overexpressing cancer by administering the above composition.

[0087] The above pharmaceutical composition may further include a pharmaceutically acceptable carrier.

[0088] In the present invention, the term "pharmaceuticalally acceptable carrier" refers to a carrier or diluent that does not irritate living organisms and does not impair the biological activity and properties of the administered compound. Acceptable pharmaceutical carriers for compositions formulated as liquid solutions include saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components, provided that they are sterile and biocompatible. Additionally, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed. Furthermore, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets.

[0089] The above pharmaceutical composition may be in various dosage forms for oral or parenteral administration. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, humectants, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, or gelatin, with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include suspensions, liquids, emulsions, and syrups, and may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents like water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, macrogol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc. may be used as bases for suppositories.

[0090] The above pharmaceutical composition may have any one formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid formulations, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories.

[0091] The composition of the present invention is administered in a pharmaceutically effective amount.

[0092] In the present invention, the term "pharmaceuticalally effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including individual type and severity, age, gender, type of cancer, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. It may also be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all of the above factors, and this can be easily determined by a person skilled in the art.

[0093] In one embodiment of the present invention, it was confirmed that the anti-CtsZ antibody of the present invention not only specifically binds to CtsZ, but also induces apoptosis and inhibits tumor formation in vivo in one or more types of cancer selected from cathepsin Z overexpressing cancers, preferably brain cancer, liver cancer, colorectal cancer, and prostate cancer, more preferably malignant brain cancer or brain tumor, more preferably glioblastoma, glioblastoma multiforme, or anaplastic astrocytoma, more preferably glioblastoma, thereby indicating that a pharmaceutical composition containing the antibody of the present invention can be usefully used in the prevention or treatment of cathepsin Z overexpressing cancers.

[0095] In another aspect, the present invention provides a method for treating cathepsin Z overexpressing cancer using the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0096] Since the “monoclonal antibody, or its antigen-binding fragment” and “cathepsin Z overexpressing cancer” of the present invention have already been described above, the description thereof is omitted to avoid excessive duplication.

[0097] The above method for treating a cathepsin Z overexpressing cancer may be a method for treating a cathepsin Z overexpressing cancer comprising the step of administering to an individual in need a pharmaceutical composition comprising a monoclonal antibody of the present invention or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising said polynucleotide, and a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is the same as described above. The above method for treating a cathepsin Z overexpressing cancer may preferably be a method for treating a cathepsin Z overexpressing cancer comprising the step of administering to an individual with cathepsin Z overexpressing cancer a composition comprising the monoclonal antibody of the present invention or a polynucleotide or an expression vector.

[0098] The above individuals include mammals such as cattle, pigs, sheep, chickens, dogs, and humans, birds, etc., and individuals in which cathepsin Z overexpression cancer is treated by administration of the above composition of the present invention are included without limitation.

[0099] At this time, the composition may be administered as a single or multiple doses in pharmaceutically effective amounts. At this time, the composition may be administered in the form of a liquid, powder, aerosol, capsule, enteric-coated tablet, capsule, or suppository. Routes of administration include, but are not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, endodermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, rectal administration, etc. However, when administered orally, since the peptide is digested, the oral composition must be formulated to coat the active agent or protect it from degradation in the stomach. Additionally, the pharmaceutical composition may be administered by any device capable of delivering the active substance to target cells.

[0100] Since the pharmaceutical composition of the present invention includes a monoclonal antibody that specifically binds to CtsZ of the present invention, when the pharmaceutical composition containing said monoclonal antibody is administered into the human body, the occurrence, proliferation, or metastasis of cathepsin Z overexpressing cancer can be inhibited or the progression prevented, thereby treating cathepsin Z overexpressing cancer.

[0102] In another aspect, the present invention provides a composition for diagnosing cathepsin Z overexpressing cancer comprising, as an active ingredient, the monoclonal antibody or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide.

[0103] Since the “monoclonal antibody, or its antigen-binding fragment” and “cathepsin Z overexpressing cancer” of the present invention have already been described above, the description thereof is omitted to avoid excessive duplication.

[0104] In the present invention, the term "diagnosis" means confirming the presence, degree (symptoms), and / or characteristics of a pathological condition. As used herein, "diagnosis of cathepsin Z overexpressing cancer" refers to confirming the pathological condition of cathepsin Z overexpressing cancer, such as whether cathepsin Z overexpressing cancer has developed, the extent of the cathepsin Z overexpressing cancer site, the location of the cathepsin Z overexpressing cancer, and the degree of cathepsin Z overexpressing cancer. For a more accurate diagnosis, it is important to accurately and rapidly distinguish cathepsin Z overexpressing cancer cells or cathepsin Z overexpressing cancer cells and / or tissues from normal cells or normal tissues.

[0105] As a specific example of the present invention, the present invention provides a monoclonal antibody that specifically binds to CtsZ, thereby enabling the specific detection of CtsZ at the protein level and making accurate diagnosis of cathepsin Z overexpressing cancer cells and / or tissues possible. In addition, by using a diagnostic composition comprising the monoclonal antibody specific to CtsZ according to the present invention, diseases related to the presence or degree of CtsZ expression or diseases mediated by CtsZ, such as cathepsin Z overexpressing cancer, can be diagnosed.

[0107] In another aspect, the present invention provides a diagnostic kit for cathepsin Z overexpressing cancer comprising the above-mentioned composition for diagnosing cathepsin Z overexpressing cancer.

[0108] Since the “monoclonal antibody, or its antigen-binding fragment” and “cathepsin Z overexpressing cancer” of the present invention have already been described above, the description thereof is omitted to avoid excessive duplication.

[0109] The above diagnostic kit for cathepsin Z overexpressing cancer may further comprise a composition, solution, or device having one or more other components suitable for the analysis method. Additionally, the above diagnostic kit for cathepsin Z overexpressing cancer may further comprise instructions.

[0110] In this specification, by providing an antibody that specifically binds to CtsZ, which is overexpressed in cathepsin Z-overexpressing cancers, a useful means is provided for measuring whether CtsZ is expressed and / or the level of expression, thereby enabling its useful application in the diagnosis of cathepsin Z-overexpressing cancers. Furthermore, when the antibody is combined with various markers, it can be used for visualizing cathepsin Z-overexpressing cancers. In particular, it can provide more accurate information regarding the confirmation of the presence of cathepsin Z-overexpressing cancers, the identification of lesion sites, and the morphological observation of cathepsin Z-overexpressing cancer sites, thereby reducing the misdiagnosis rate associated with cathepsin Z-overexpressing cancers and contributing to early diagnosis. Additionally, when a bioactive substance, such as a drug, is combined with the antibody, the bioactive substance can be specifically delivered to colorectal cancer, and thus can be used as a composition for targeted delivery of the bioactive substance to cathepsin Z-overexpressing cancers.

[0112] In another aspect, the present invention provides a method for providing information necessary for diagnosing a cathepsin Z overexpressing cancer, comprising: (a) contacting a biological sample isolated from an individual suspected of having a cathepsin Z overexpressing cancer with the monoclonal antibody, or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector comprising the polynucleotide; (b) measuring the expression level of a cathepsin Z protein from the biological sample; and (c) determining that the cancer is cathepsin Z overexpressing cancer if the expression level of the cathepsin Z protein measured in step (b) is higher than that of a control group.

[0113] The monoclonal antibody, cathepsin Z overexpressing cancer, individual, and CtsZ are as described above. A method for providing information necessary for the diagnosis of cathepsin Z overexpressing cancer involves reacting the monoclonal antibody specific to CtsZ according to the present invention with an isolated biological sample of an individual suspected of having cathepsin Z overexpressing cancer, and measuring the expression level of the CtsZ protein through the formation of an antigen-antibody complex, thereby providing information for the diagnosis of cathepsin Z overexpressing cancer. Since CtsZ is overexpressed in cathepsin Z overexpressing cancer cells, if the expression level of CtsZ is higher than that of a control group such as normal cells or tissues, the individual can be determined to have cathepsin Z overexpressing cancer.

[0114] In the present invention, the term "biological sample" may include, but is not limited to, tissues, cells, whole blood, serum, plasma, tissue autopsy samples (brain, skin, lymph nodes, spinal cord, etc.), saliva, urine, cell culture supernatant, ruptured eukaryotic cells, and bacterial expression systems. These biological samples may be reacted with the antibody of the present invention, with or without manipulation, to determine the presence or expression level of the CtsZ protein, or whether the cancer is cathepsin Z overexpressing.

[0115] The expression level of the cathepsin Z protein can be achieved by measuring the expression level of the cathepsin Z protein bound to a monoclonal antibody or its antigen-binding fragment in the biological sample through the formation of an antigen-antibody complex, but is not limited thereto.

[0116] In the present invention, the term "antigen-antibody complex" refers to a conjugate of a CtsZ protein antigen in a sample and a monoclonal antibody according to the present invention that recognizes it. The formation of such an antigen-antibody complex can be detected by any method selected from the group consisting of colorimetric methods, electrochemical methods, fluorimetric methods, luminometric methods, particle counting methods, visual assessment methods, and scintillation counting methods. However, the method is not necessarily limited to these methods and various applications are possible.

[0117] In the present invention, various labeling agents may be used for detecting antigen-antibody complexes. Specific examples may be selected from the group consisting of enzymes, fluorescent agents, ligands, luminescent agents, microparticles, and radioisotopes, but are not necessarily limited to these.

[0118] Enzymes used as detection labels include acetylcholinesterase, alkaline phosphatase, β-D-galactosidase, horseradish peroxidase, β-latamase, etc., and fluorescent agents include fluorescein, Eu 3+ , Eu 3+ It includes chelates or cryptates, etc., and ligands include biotin derivatives, etc., and luminescent materials include acridinium esters, isoluminol derivatives, etc., and microparticles include colloidal gold, colored latex, etc., and radioactive isotopes include 57 Co, 3 H, 125 I, 125 It includes I-Bolton Hunter reagents, etc.

[0119] Preferably, antigen-antibody complexes can be detected using an enzyme-linked immunosorbent assay (ELISA). The enzyme-linked immunosorbent assay (ELISA) includes various ELISA methods, such as a direct ELISA using a labeled antibody that recognizes an antigen attached to a solid support, an indirect ELISA using a labeled secondary antibody that recognizes a capture antibody in a complex of antibodies that recognize an antigen attached to a solid support, a direct sandwich ELISA using another labeled antibody that recognizes an antigen in a complex of antibodies attached to a solid support and an antigen, and an indirect sandwich ELISA using a labeled secondary antibody that recognizes this antibody after reacting with another antibody that recognizes an antigen in a complex of antibodies attached to a solid support and an antigen.

[0120] The above monoclonal antibodies may have a detection label, and if they do not have a detection label, these monoclonal antibodies can be captured and confirmed by treating with another antibody having a detection label.

[0121] In one embodiment of the present invention, by confirming that the anti-CtsZ antibody of the present invention specifically recognizes CtsZ using an antigen-antibody reaction, it was shown that the antibody of the present invention can be usefully used for the diagnosis of cathepsin Z overexpressing cancer.

[0123] Hereinafter, a monoclonal antibody according to the present invention, or an antigen-binding fragment thereof, will be described in detail with reference to examples.

[0125] <Example>

[0126] Materials and Methods

[0127] 1. Ingredients

[0128] DNA sequencing was performed by Bionics Co., Ltd. Ni-NTA resin and HRP-conjugated streptavidin were purchased from Thermo Fisher Scientific (USA). MiniTrap G-25 columns, PD-10 desalting columns, and CNBr-Activated Sepharose 4B were purchased from Cytiva (USA). HRP-conjugated anti-6x his tag antibody and HRP-conjugated anti-human Fc antibody were purchased from Invitrogen (USA). Human Integrin αVβ3 was purchased from Acrobiosystems (USA). Human fibronectin and human integrin αV / CD51 biotinylated antibody were purchased from R&D Systems (USA). HRP-conjugated anti-HA tag antibody was obtained from Bethyl (USA). Protein A resin was purchased from GenScript (USA).

[0130] 2. Recombinant CtsZ Protein

[0131] Human breast cancer cells (MDA-MB-231) at 1.0 × 10⁶ in FBS medium 6 The CtsZ gene was obtained by culturing until the cell count reached 1 / mL.

[0132] Specifically, cultured MDA-MB-231 cells were centrifuged to obtain a pellet, and RNA was extracted using the Trizol RNA extraction method. MDA-MB-231 cDNA was synthesized using reverse transcription PCR with the extracted RNA as a template. CtsZ gene PCR was performed using the MDA-MB-231 cDNA as a template (Tables 1 to 3). Additionally, through CtsZ gene PCR, the Kozak sequence (GCCGCCACCCATGGG) was added to the N-terminus of CtsZ, and a 6x-His tag was added to the C-terminus. The amplified CtsZ gene was inserted into the XbaⅠ and XhoⅠ sites of pcDNA3.4. 30 mL of Expi-293FTM cells were transfected with the pcDNA3.4-CtsZ plasmid and cultured for 20 hours, followed by incubation with an inducer for 6 days. After incubation, the medium was harvested by centrifugation (3,500 g, 20 min, 4 ℃) and filtered through a 0.45 µm syringe filter. The filtered medium was incubated with Ni-NTA resin pre-equilibrated to 1X PBS pH 7.4 at 4 ℃ for 2 hours and loaded onto a disposable column. After washing with equilibration buffer for 10 RV (Resin Volume), the protein eluent was eluted in PBS pH 7.4 using a gradient of 5 to 200 mM imidazole. Finally, the eluent was buffered with PBST (0.01% Tween-20) at pH 7.4 using a PD-10 desalting column. The purified CtsZ was stored at -80 ℃ until use. The primers used in the above PCR are shown in Table 1 below, and the PCR conditions are shown in Tables 2 and 3 below.

[0133] division nucleotide sequence Forward Primer TATCAATCTAGAGCCGCCACCATGGCGAGGCGCGGGCCAG overhang TATCAA Xbal TCTAGA Kozak GCCGCCACCATGG annealing site CCATGGCGAGGCGCGGGCCAG Reverse Primer TATCAACTCGAGTCATTAGTGGTGATGGTGATGATGAACGATGGGGTCCCCAAATGTACAGTGCTCCCTC overhang TATCAA Xhol CTCGAG stop codon TCATTA annealing site AACGATGGGGTCCCCAAATGTACAGTGCTCCTC

[0134] PCR materials volume Platinum™ SuperFi II PCR Master Mix (Invitrogen™, 12368010) 25 ㎕ Primer(Forward / Reverse) 2.5 ㎕ / 2.5 ㎕ cDNA template 2 ㎕ (2 ㎍) Nuclease 18 ㎕ Total 50 ㎕

[0135] PCR conditions volume Initial denaturation 98 ℃, 30 s (1 cycle) Denaturation 98 ℃, 10 s 30 cycle Annealing 65 ℃, 10 s Extension 72 ℃, 30 s Final extension 72 ℃, 5 m (1 cycle)

[0137] 3. RNA extraction using Trizol

[0138] The MDA-MB-231 cell pellet from Method 2 above and 1 mL of Trizol were mixed by vortexing for 10 seconds in a 1.5 mL e-tube. The mixture was incubated at room temperature for 5 minutes. 200 μL of chloroform was added to the mixture and vortexed for 20 seconds. The mixture was incubated at room temperature for 3 minutes. The clear supernatant was transferred to a new e-tube after phase separation centrifugation (13,000 g, 15 min, 4 ℃). 500 μL of isopropyl alcohol was added to the supernatant, vortexed for 5 seconds, and reacted at 25 ℃ for 10 minutes. To remove the supernatant, the pellet was centrifuged at 12,000 rpm for 10 minutes and then resuspended in 1 mL of 70% ethanol. After the second centrifugation, the supernatant was removed and the pellet was dried for at least 10 minutes. The completely dried pellet was dissolved in RNA-free water.

[0140] 4. ELISA for integrin αVβ3 binding to purified CtsZ

[0141] 1XPBS pH 7.4 containing 200 ng CtsZ was coated onto each well of a 96-well high-binding plate at 4°C for 16 hours, washed twice with wash buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM MnCl2, 0.05% Tween-20), and then blocked with blocking buffer (wash buffer containing 3% BSA) at room temperature for 2 hours. After washing twice with wash buffer, 200 nM, 1 / 3x integrin αVβ3-containing dilution buffer (wash buffer containing 0.5% BSA) was bound at room temperature for 2 hours. After washing four times with wash buffer, biotinylated anti-human integrin αVβ3 antibody (diluted 1:100 with dilution buffer) was treated at room temperature for 1 hour. After washing four times with wash buffer, HRP-conjugated streptavidin was treated at room temperature for 1 hour. After washing four times with wash buffer, ultra TBM substrate was added and reacted for 2 minutes, after which the reaction was stopped with 2M H2SO4. The KD value was calculated by graphing the absorbance at 450 nm using Prism7 software.

[0143] 5. Manufacture of CTSZ Conjugated Resin

[0144] Using a pre-equilibrated MiniTrap G-25 column, the buffer for purified CtsZ was changed to 1X PBS pH 7.4. 0.3 mg of CtsZ and 0.1 mL of pre-washed CNBr (cyanogen bromide)-activated resin were mixed in a spin column at 4 °C for 16 hours. After washing three times with 1X PBS, the remaining active groups were blocked with 0.1 M Tris-HCl pH 8.0 for 2 hours. After washing three times with 1X PBS, 0.9 mL of 1X PBS was added to prepare a 10% (v / v) resin slurry, which was then stored at 4 °C.

[0146] 6. Biopanning for CNBr-conjugated CtsZ

[0147] For the first round of biopanning, 100 μL of resin solution (10 μL resin, 30 μg binding protein (CNBr-conjugated CtsZ)) was first placed in a centrifuge tube filter and centrifuged at 500 g for 30 seconds. Subsequently, the sample was blocked with 700 μL of 3% BSA at room temperature for 2 hours. After washing three times with 1X PBS pH 7.4, 200 μL of the phage library was incubated at 4 ℃ for 16 hours. Subsequently, an M13 phage library labeled with scFv was provided by Professor Hyun-Bo Shim (Ewha Womans University, Korea) (Yang, HY, et al Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Molecules and cells, 2009. 27(2): p. 225-235)

[27] . For low pH elution, 200 μL of elution buffer (100 mM glycine pH 2.2, 1% BSA) was added to the tube and the tube was incubated at room temperature for 10 minutes. Finally, the phage eluent was obtained by centrifugation (500 g, 30 seconds). For neutralization, 40 μL of 1 M Tris-HCl pH 8.0 was immediately added.

[0148] For titration, 10 μL of the neutralized phage eluent was serially diluted using 1X PBS. The diluted sample E.coli ER2738(OD 600 Infected at room temperature for 30 minutes with (= 0.6-0.8), then sprinkled onto an LB / agar plate containing carbenicillin.

[0149] For phage amplification, 2 mL of E.coli ER2738(OD 600SB medium containing (= 0.6-0.8, containing tetracycline) was infected with 200 μL of the neutralized phage eluent at 110 rpm and 37 ℃ for 1 hour. 2 mL of infected cells were transferred to 10 mL of SB medium, 6 μL of carbenicillin (100 μg / mL) was added, and the cells were incubated at 180 rpm and 37 ℃ for 1 hour. Subsequently, 12 mL of infected cells were transferred to 30 mL of SB medium, 30 μL of carbenicillin and 42 μL of M13KO7 helper phage (2.4 × 10¹² pfu / mL) (NEB, UK) were added, and the cells were incubated at 30 ℃, 16 h, and 180 rpm. The cells were centrifuged at 3,500g for 30 minutes, and the supernatant was transferred to a new 50 mL conical tube. 1.6 g of PEG 8000 and 1.2 g of NaCl were mixed into the supernatant and reacted at 37 °C for at least 10 minutes to completely dissolve the components. The mixture was incubated on ice for 4 hours. Subsequently, the pellet obtained by centrifugation at 15,000g for 1 hour was resuspended in 400 μL of PB buffer (1XPBS, 1% BSA). Finally, the supernatant was centrifuged (15,000g, 10 min) to recover the supernatant and filtered using a 0.22 μm PES syringe filter. The filtered supernatant was stored at 4 °C until use.

[0150] Round 2 and Round 3 biopanning were conducted under the same conditions as Round 1 biopanning, but Round 4 and Round 5 biopanning were conducted without the aforementioned amplification process (experimental results showed that starting from Round 4 biopanning, a problem occurred where the in-frame rate dropped sharply to below 5% when the amplitude process was performed).

[0152] 7. Separation of the peripheral cytoplasmic fraction containing scFv

[0153] ER2738 infected with the above phage was plated onto an LB / agar plate containing carbenicillin. 750 μL of SB medium containing carbenicillin was filled into a 96-deep well plate, and a single colony was inoculated into each well. The 96-deep well plate was cultured (4 hours, 37°C, 180 rpm), and 75 μL of 10 mM IPTG was added to each well. IPTG induction was performed at 180 rpm for 16 hours at 30°C. The induced cells were centrifuged (4,000 rpm, 20 minutes, 4°C) to remove the supernatant, and the deep well plate was placed on ice.

[0154] The pellet was gently resuspended by adding 200 μL of 1XTES buffer (20% sucrose, 50 mM Tris-HCl pH 8.0, 1 mM EDTA) to ice. To induce osmotic shock and disrupt the outer membrane of the cells, 300 μL of 0.2XTES buffer was added and incubated with ice for 30 minutes. The supernatant was recovered by centrifugation (4000 rpm, 20 min, 4°C). The supernatant contained a peripheral cytoplasmic fraction containing scFv.

[0156] 8. Dot Blot Analysis

[0157] 2 μL of the above peripheral cytoplasmic fraction was transferred to the NC membrane using a 0.2-10 μL multi-pipette. Additionally, 2 μL of PBS and 10-100 ng of scFv were transferred to a positive control. The NC membrane was incubated with PBS containing 5% skim milk at room temperature for 1 hour. Afterward, it was washed four times for 5 minutes each with PBST (0.05% tween-20). For the antibody reaction, HRP-conjugated anti-HA antibody was diluted 1:3000 in PBST (0.05%) and incubated at room temperature for 1 hour. After washing four times for 5 minutes each with PBST (0.05% tween-20), a chemiluminescent substrate was applied, and dots were detected using LAS4000.

[0159] 9. Peripheral cytoplasmic fraction ELISA

[0160] 100 μL of CtsZ (200 ng / well) was coated onto a 96-well high binding plate at 4°C for 16 hours. In the blocking step, 300 μL of 3% BSA in 1X PBS pH 7.4 was added to each well and incubated at room temperature for 2 hours. After washing 4 times with 300 μL of 1X PBS, 100 μL of the peripheral cytoplasmic fraction (obtained in previous step 7) was added to each well and incubated at room temperature for 2 hours. After washing 4 times with 300 μL of PBST (0.05% Tween-20), 100 μL of HRP-conjugated anti-HA antibody diluted 1:3000 in PBST (0.05%) was incubated at room temperature for 1 hour. After washing four times with 300 μL of PBST (0.05% Tween-20), 100 μL of ultra TMB solution was added and reacted for 5 minutes, then terminated with 2M H2SO4.

[0162] 10. Selection of scFv clones specific to CtsZ

[0163] CtsZ-specific scFv clones were selected from 40 scFv clones by performing a negative selection ELISA. Non-specific binding activity with integrin (ITG) and fibronectin (FN) was measured by ELISA. Specifically, in the antigen coating step of the ELISA, 100 μL of Integrin αVβ3 or Fibronectin (200 ng / well) was coated in 1XPBS pH 7.4 instead of CtsZ, and the subsequent process was the same as the peripheral cytoplasmic fraction ELISA method (previous step 9).

[0165] 11. Expression and Purification of Anti-CtsZ scFv

[0166] The pComb3X-scFv plasmid was used to transform TOP10F competent cells. The resulting colonies were inoculated into 10 mL of SB medium (containing carbenicillin and tetracycline) and pre-cultured at 37 °C for 16 hours. For the main culture, the pre-cultured cells were transferred to 500 mL of SB medium (containing carbenicillin) and cultured at 37 °C with an OD level. 600 The procedure was carried out under conditions where growth was 0.6–0.8. IPTG was added to achieve a final concentration of 1 mM IPTG, and IPTG induction was performed at 30 ℃ for 16 hours. Subsequently, cells were harvested by centrifugation (3,500 g, 20 min, 4 ℃). 35 mL of cold 1XTES buffer (20% sucrose, 50 mM Tris-HCl pH 8.0, 1 mM EDTA) was added to the harvested cells, and the mixture was resuspended. Then, lysozyme was added to achieve a final concentration of 1 mg / mL, and the cells were incubated on ice for 30 minutes. Finally, 0.25 mL of 1 M MgCl2 was added to inactivate the remaining EDTA, and the cells were incubated on ice for 10 minutes. Subsequently, to recover the peripheral cytoplasmic fraction, the sample was centrifuged (10,000 g, 20 min, 4°C) and the supernatant was collected. To facilitate protein-resin binding, 1 mL of Ni-NTA resin (eq. buffer:resin = 1:1) pre-equilibrated with 0.05% PBST was mixed with the peripheral cytoplasmic fraction and incubated at 4°C for 1 hour. The protein-resin mixture was packed into a disposable column and washed with 0.05% PBST until the resin volume reached 20 RV (Resin Volume), and then further washed with 0.05% PBST containing 5, 10, and 50 mM imidazole to reach 10 RV, respectively. The protein eluent was eluted to 2.5 RV with 0.05% PBS containing 200 mM imidazole. Finally, the above eluent was buffered with 1XPBS pH 7.4 using a PD-10 desalting column. The purified scFv clones were stored at -80 ℃ until use.

[0168] 12. ELISA for anti-CtsZ scFv binding to CtsZ

[0169] 100 μL of CtsZ (200 ng / well) dissolved in coating buffer (1XPBS pH 7.4) was coated onto a 96-well high-binding plate at 4°C for 16 hours. In the blocking step, 300 μL of blocking buffer (wash buffer containing 3% BSA) was added to each well and incubated at room temperature for 2 hours. After washing four times with 300 μL of wash buffer (20 mM Tris, 150 mM NaCl, 1 mM MnCl2, 0.05% Tween-20 pH 7.4), 700 nM, 1 / 4-fold purified scFv clones were bound at room temperature for 2 hours. After washing four times with 300 μL of wash buffer, 100 μL of HRP-conjugated anti-HA antibody diluted 1:3000 in dilution buffer (wash buffer containing 0.5% BSA) was conjugated at room temperature for 1 hour. After washing four times with 300 μL of wash buffer, 100 μL of ultra TMB solution was added and reacted for 2 minutes, after which the reaction was terminated with 2M H2SO4. The KD value was calculated using Prism7 software after graphing the absorbance at 450 nm.

[0171] 13. Expression and Purification of Anti-CtsZ IgG

[0172] To express anti-CtsZ IgG in mammalian cells, 30 mL of pcDNA3.4-IgH and pcDNA3.4-IgL plasmids were added to Expi-293F TMCells were transfected and cultured at 37°C, 20 h, 120 rpm, and 8% CO2. Inducers were added, and the cells were cultured for 6 days. The culture medium was harvested by centrifugation (3,500 g, 20 min, 4°C) and filtered using a 0.45 µm syringe filter. Then, for protein-resin binding, 0.5 mL of rProtein A resin (eq. buffer:resin = 1:1), pre-equilibrated with 1X PBS at pH 7.4, was mixed with the medium and incubated at 4°C for 2 hours. The protein-resin mixture was packed into a disposable column, washed with 1X PBS at pH 7.4 until the resin volume reached 20 RV (Resin Volume), and eluted with 2.33 mL of IgG elution buffer. After elution, 233 μL of neutralization buffer was immediately mixed to neutralize the eluent. The neutralized eluent was buffered with 1XPBS pH 7.4 using a PD-10 column. The purified anti-CtsZ IgG clone was stored at -80°C until use.

[0174] 14. ELISA for anti-CtsZ IgG binding to CtsZ

[0175] 100 μL of CtsZ (200 ng / well) dissolved in coating buffer (1XPBS pH 7.4) was coated onto a 96-well high-binding plate at 4 °C for 16 hours. In the blocking step, 300 μL of blocking buffer (wash buffer containing 3% BSA) was added to each well and incubated at room temperature for 2 hours. Purified IgG clones at 300 μL of wash buffer (20 mM Tris, 150 mM NaCl, 1 mM MnCl2, 0.05% Tween-20 pH 7.4), 10 nM, 1 / 4-fold (#1, 2, 3, 4, 6, 7), 600 nM, 1 / 4-fold (#5, 8), or 2 μM, 1 / 4-fold (#9) were bound at room temperature for 2 hours. After washing four times with 300 μL of wash buffer, 100 μL of HPR-conjugated anti-human Fc antibody diluted 1:2,500 in dilution buffer (wash buffer containing 0.5% BSA) was conjugated at room temperature for 1 hour. After washing four times with 300 μL of wash buffer, 100 μL of ultra TMB solution was added and reacted for 2 minutes, after which the reaction was terminated with 2M H2SO4. The KD value was calculated using prism7 software after graphing the absorbance at 450 nm.

[0177] Test Example 1: Preparation and Screening of Anti-CtsZ Antibodies

[0178] 1-1. Human CtsZ Expression and Purification

[0179] 1-1-1. Human CtsZ Expression and Purification Process

[0180] 1) cDNA cloning and transfection: CtsZ is upregulated in the breast cancer cell line MDA-MB-231. Therefore, RNA was extracted from MDA-MB-231 cells to obtain RNA containing the CtsZ gene. After synthesizing cDNA via RT-PCR, a Kozak sequence was added to the N-terminus to increase protein expression in mammalian cells, and a 6x-His tag was added to the C-terminus for purification during the amplification process of the CtsZ gene (Fig. 2). Subsequently, the cDNA was cloned into a vector (pcDNA3.4) for animal cell expression, and the resulting DNA was transferred to animal cells (Expi293F TM Transfected into cells (CtsZ is expressed in animal cells because it has two glycosylation sites).

[0181] 2) Medium separation: Since CtsZ itself contains a signal sequence, the CtsZ expressed in the animal cells is released into the medium. The medium was recovered by centrifugation at 3000 g for 30 minutes, and the cells were purified after being filtered through a 0.2 µm filter.

[0182] 3) Purification: The medium released with CtsZ was purified using a Ni-NTA affinity column (Fig. 3). Specifically, the medium released with CtsZ was incubated with Ni-NTA resin at 4°C for 2 hours. After flow-through in the column and washing with a buffer containing imidazole, CtsZ protein was obtained using elution buffer (PBS pH 7.4 + 100 mM or 200 mM imidazole). Subsequently, the buffer was exchanged with PBST pH 7.4 (0.01% tween-20) via a desalting column, and the sample was dispensed into single-use portions and stored at -80°C.

[0183] 1-1-2. SDS-PAGE and Western blot analysis

[0184] CtsZ expression was confirmed by Western blot using an anti-6X his tag antibody.

[0185] Specifically, SDS-PAGE was performed using a 12% SDS-PAGE gel, and CtsZ protein was transferred to a PVDF membrane activated with methanol for 10 minutes for 2 hours. The PVDF membrane to which the protein was transferred was blocked with 5% skim milk-containing PBST (0.05% tween-20) at room temperature for 2 hours, followed by 4 washes with 0.05% PBST for 5 minutes each. An HRP-conjugated Anti-6x His tag antibody was diluted 5000:1 and reacted at room temperature for 1 hour, followed by washing under the same washing conditions as before. After a chemiluminescence reaction to observe immunoreactive protein bands, the bands were detected using a Western blot LAS4000 (Fig. 4).

[0186] Looking at Figure 4, it can be seen that while the size of CtsZ predicted by amino acids is approximately 33 kDa, the actual size of CtsZ analyzed by SDS-PAGE is approximately 37 kDa. This is presumed to be due to the two glycosylation sites present in the CtsZ gene (Yield: 5.75 mg CtsZ / 30 mL medium).

[0187] 1-1-3. Measurement of the binding affinity of integrin αVβ3 binding to CtsZ

[0188] Since CtsZ has an RGD motif in the pro-region that binds to integrins, particularly integrin αVβ3, the binding affinity of integrin αVβ3 purchased from Acrobiosystems was measured to confirm that the purified CtsZ has an active form. As a result, the binding curve between CtsZ and integrin αVβ3 showed a specific interaction, and the KD value was found to be approximately 137 nM (Fig. 5).

[0190] 1-2. Biopanning of CtsZ-CNBr Resin Immobilization and Single-Chain Surface Display Phage Libraries

[0191] Instead of the plate-antigen binding method, which involves relatively low antigen surface exposure, the resin-antigen binding method, which maximizes antigen surface exposure, was selected. While the antigen binding capacity in the conventional method is approximately 500 ng antigen / cm², the new method is approximately 50 µg antigen / 10 µL, which is estimated to increase the antigen binding capacity by about 100 times. Accordingly, the phage display biopanning of the present invention has a high probability of finding the desired clone. In fact, the resin capacity was found to be approximately 56 µg CtsZ / 10 µL in the resin-antigen binding test. The resin-antigen binding test was measured using the nanodrop method ((amount of bound antigen) - (amount of antigen in the buffer filtered by the centrifuge filter tube after binding)). This method was performed using a centrifuge filter tube instead of a plate, making the panning cycle easier.

[0192] 1-2-1. CtsZ-CNBr Resin Immobilization Process

[0193] 1) CNBr resin activation: The CNBr resin was washed with 1 mM HCl to remove additives present in it. Subsequently, the remaining HCl was washed with PBS to bind to CtsZ.

[0194] 2) CtsZ-CNBr resin binding: CNBr resin washed with PBS and CtsZ were mixed in a ratio of CNBr resin : CtsZ = 100 ul : 0.3 mg and incubated at 4 ℃ for 16 hours.

[0195] 3) Blocking and washing: The resin was washed with PBS using a spin column and incubated with 0.1 M Tris-Cl pH 8.0 at room temperature for 2 hours to block the active groups remaining on the CNBr resin. Afterward, the resin was washed again with PBS, and the CtsZ-bound CNBr resin was dissolved in 0.9 mL of PBS to form a 10% (v / v) slurry and stored at 4 ℃ (Fig. 6).

[0196] 1-2-2. Biopanning of Single-Chain Surface Display Phage Libraries

[0197] 1) Phage Binding: 100 µl of CtsZ-CNBr resin was placed in a spin column and centrifuged at 500 g for 10 seconds to remove the buffer. Then, 3% BSA was added and the column was blocked at room temperature for 2 hours. Afterward, the column was washed with PBS and the OPAL phage library (~2*10 12 cfu / 200 ul) was added and incubated at 4 ℃ for 16 hours (Fig. 7) (Yang, HY et al. , (2009). Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Molecules and cells, 27, 225-235).

[0198] Figure 8 is a schematic diagram briefly illustrating the biopanning process of the present invention.

[0199] 2) Phage elution: After performing the washing process according to the washing conditions of each round of biopanning, low pH elution buffer (pH 2.2) was added and incubated at room temperature for 10 minutes. Afterward, neutralization buffer (pH 8.0) was added to the phage elution and mixed, and then stored at 4 ℃.

[0200] 3) Phage Amplification: OD 600 ER2738 cells grown to 0.6 were infected with the phage eluent and cultured at 37 ℃ for 2 hours, then scaled up to 42 mL. Helper phage M13KO7 (2.4*10 12(pfu / mL) was added and incubated at 37°C for 1 hour. Subsequently, kanamycin antibiotic was added and incubated at 30°C for 16 hours. Cells were separated by centrifugation at 3500 g for 30 minutes, and 4% PEG and 3% NaCl were added to the supernatant to dissolve thoroughly, followed by incubation at 4°C for 4 hours. Phage pellets were obtained by centrifugation at 15000 g for 1 hour, resuspended in 1% BSA / PBS buffer, filtered through 0.2 μm, and stored at 4°C.

[0201] 4) The above steps 1) - 3) were repeated up to the 3rd round biopanning, and for the 4th and 5th round biopannings, the amplification step 3) was omitted and the phage binding process was carried out using the phage eluent from the previous round.

[0202] 5) Meanwhile, ER2788 infected with the above phage was plated on an LB / agar plate containing carbenicillin to determine the input and output phage titers (Figs. 9 and 10, and Figs. 13 and 14).

[0203] Looking at Figures 9 and 10, and Figures 13 and 14, it appears that the titer increases with each round in both the first biopanning (CtsZ biopanning #1) and the second biopanning (CtsZ biopanning #2), so it can be predicted that scFv clones specific to CtsZ are enriched with each round of biopanning.

[0204] 1-2-3. Dot Blot Analysis

[0205] We intended to examine the change in the in-frame percentage of biopanning output depending on whether the amplification process was performed when transitioning from round 3 to round 4. Dot blot analysis was performed to analyze the in-frame percentage of biopanning output.

[0206] As a result of the first biopanning, it can be seen that the in-frame percentage of the 4th round output decreases sharply compared to the 3rd round output after the amplification process when moving from the 3rd round to the 4th round (3rd round output: 31 / 96, 32.2% → 4th round output: 5 / 96, 5%) (Figs. 11a and 12a).

[0207] However, when performing a scFv ELISA with 3 round output, one CtsZ-specific clone was found (Figs. 11a and 11c). Therefore, during the second biopanning, the amplification process was omitted when moving from round 3 to round 4.

[0208] As a result of the second biopanning, it can be seen that the output in-frame percentage after proceeding with 4 rounds and 5 rounds without amplification does not decrease but rather increases (4 round output: 83 / 96, 86%, 5 round output: 26 / 26, 100%) (Figs. 15a and 17a).

[0209] Meanwhile, a plate binding test was performed to confirm whether the purified CtsZ antigen binds to the plate (Fig. 11b). CtsZ was bound to a high-binding 96-well plate at different concentrations (1000 ng, 1 / 3 fold) and detected using an HRP-conjugated anti-6X His antibody. As a result, it was confirmed that CtsZ binds sufficiently to the plate when at least 300 ng of the purified CtsZ antigen is bound. Accordingly, in the subsequent ELISA experiment, the amount of CtsZ used to bind to the plate was fixed at 300 ng.

[0210] 1-2-4. Selection of CtsZ-specific single-chain antibody clones by scFv ELISA

[0211] A total of 96 scFv clones specific to CtsZ were obtained by performing scFv ELISA and selecting clones with an intensity of 0.3 or higher (1st panning 3rd round output: 1 type, 2nd panning 4th round output: 76 types, 2nd panning 5th round output: 19 types) (Figs. 16a, 16b and 18).

[0212] 1-2-5. Gene sequencing analysis of selected CtsZ-specific single-chain antibody clones

[0213] As a result of genetic analysis, a total of 39 different clones were obtained excluding enriched sequences (1st panning 3rd round output: 1 type, 2nd panning 4th round output: 30 types, 2nd panning 5th round output: 8 types) (Figs. 19 to 23).

[0214] Subsequently, in order to select scFv clones with stronger CtsZ specificity among the 39 different scFv clones mentioned above, scFv clones satisfying all of the following conditions were selected via ELISA: 1) high-intensity specific binding to CtsZ, 2) low-intensity non-specific binding to integrin αVβ3, and 3) low-intensity non-specific binding to fibronectin. As a result, 9 CtsZ-specific scFv clones satisfying all three of the above conditions were selected (#1: 4R_A4, #2: 5R_G9, #3: 4R_C3, #4: 4R_E1, #5: 5R_F4, #6: 5R_F10, #7: 5R_F2, #8: 4R_D1, #9: 5R_G5) (Figs. 24 and 25).

[0216] 1-3. Purification and Binding Affinity of CtsZ-Specific scFv

[0217] Since the above-described process for selecting CtsZ-specific scFv clones was performed using the cytoplasmic fraction surrounding scFv expression, it is essential to individually verify the purified scFv clones for more accurate results. Therefore, each clone was expressed in the pComb3X plasmid of TOP10F cells to obtain the cytoplasmic fraction via osmotic shock, and purified using Ni-NTA affinity chromatography. The nine selected scFv clones showed a purity of over 95% by SDS-PAGE analysis (Fig. 26). In addition, the KD values ​​of the scFv clones for CtsZ were determined by measuring binding affinity via ELISA. Each scFv clone #1, #2, #3, #4, #5, #6, #7, #8 and #9 showed nanomolar KD values ​​for CtsZ (KD values ​​#1: 5.9 nM, #2: 3.1 nM, #3: 3.0 nM, #4: 1.5 nM, #5: 1.7 nM, #6: 2.7 nM, #7: 11.4 nM, #8: 6.8 nM, #9: 69.1 nM) (Fig. 26).

[0219] Test Example 2: Analysis of the effect of treatment with anti-CtsZ antibody on the death of MES-type brain tumor stem cells

[0220] The anti-CtsZ antibody prepared in Test Example 1 above was treated with MES-type brain tumor stem cells to analyze the effect of the anti-CtsZ antibody of the present invention on the death of MES-type brain tumor stem cells.

[0221] Specifically, after treating MES-type brain tumor stem cells (83NS cells) with the anti-CtsZ antibody (#6) prepared in Test Example 1 (75 µg / ml), the cell cycle was analyzed daily using FACS (Mylteni, MACSQuant analyzer 10) to measure the SubG1 fraction indicating apoptosis. The 83NS cells were cultured in DMEM / F12 medium containing B27 supplement (0.04% v / v) and EGF / bFGF (20 / 10 ng / ml), and the cell concentration at the time of antibody treatment was 5 x 10⁶ 4 It was / ml.

[0222] As a result, it can be seen that the anti-CtsZ antibody effectively kills MES brain tumor stem cells, as the subG1 fraction, which indicates the death of 83NS cells, is significantly increased due to treatment with the anti-CtsZ antibody of the present invention (Figs. 27 and 28).

[0224] From the foregoing description, a person skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.

Claims

Claim 1 A monoclonal antibody that specifically binds to cathepsin Z, or an antigen-binding fragment thereof, comprising: a heavy chain variable region including a CDR1 region described by SEQ ID NO. 31, a CDR2 region described by SEQ ID NO. 32, and a CDR3 region described by SEQ ID NO. 33; and a light chain variable region including a CDR1 region described by SEQ ID NO. 34, a CDR2 region described by SEQ ID NO. 35, and a CDR3 region described by SEQ ID NO.

36. Claim 2 A monoclonal antibody or its antigen-binding fragment according to claim 1, characterized in that the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, scFv, Fv, dsFv, and diabody. Claim 3 A monoclonal antibody of claim 1 or 2, or a polynucleotide encoding its antigen-binding fragment. Claim 4 In paragraph 3, the polynucleotide is characterized by being composed of the sequence of SEQ ID NO.

78. Claim 5 An expression vector comprising the polynucleotide of claim 3. Claim 6 Isolated host cells transformed with the expression vector of paragraph 5. Claim 7 A pharmaceutical composition for the prevention or treatment of cathepsin Z overexpressing cancer, comprising as an active ingredient a monoclonal antibody of claim 1 or 2 or its antigen-binding fragment, a polynucleotide encoding said monoclonal antibody or its antigen-binding fragment, or an expression vector containing said polynucleotide. Claim 8 A composition according to claim 7, characterized in that the cancer is one or more selected from brain cancer, liver cancer, colorectal cancer, and prostate cancer. Claim 9 A composition according to claim 8, characterized in that the brain cancer is a malignant brain cancer or a brain tumor. Claim 10 A composition according to claim 9, characterized in that the malignant brain cancer is glioblastoma or glioblastoma multiforme. Claim 11 A composition according to claim 9, characterized in that the brain tumor is an anaplastic astrocytoma. Claim 12 A composition for diagnosing cathepsin Z overexpressing cancer, comprising a monoclonal antibody of claim 1 or 2 or its antigen-binding fragment, a polynucleotide encoding said monoclonal antibody or its antigen-binding fragment, or an expression vector comprising said polynucleotide. Claim 13 A diagnostic kit for cathepsin Z overexpressing cancer comprising the composition and instructions of claim 12. Claim 14 (a) a step of contacting a biological sample isolated from an individual suspected of having a cathepsin Z overexpression cancer with a monoclonal antibody of claim 1 or 2 or its antigen-binding fragment, a polynucleotide encoding the monoclonal antibody or its antigen-binding fragment, or an expression vector containing said polynucleotide; (b) a step of measuring the expression level of a cathepsin Z protein from said biological sample; and (c) a step of determining that the cancer is cathepsin Z overexpression cancer if the expression level of the cathepsin Z protein measured in step (b) is higher than that of a control group; comprising a method for providing information necessary for the diagnosis of a cathepsin Z overexpression cancer.

Citation Information

Patent Citations

  • Antibody against cathepsin and its utilization

    JP2000050885A